Abaloparatide Disease Interactions

Patients known to have an underlying hypercalcemic disorder, such as primary hyperparathyroidism, should not be treated with parathyroid hormone and its analogs because of the risk of exacerbating hypercalcemia.

Parathyroid hormone and its analogs should not be used in patients who are at increased baseline risk for osteosarcoma. These agents should only be used if the potential benefits are considered to outweigh the potential risks. Monitor these patients according to clinical guidelines. Patients with bone metastases or a history of skeletal malignancies should not be treated with these agents.

No dosage adjustment is required for patients with mild, moderate, or severe renal impairment. Patients with severe renal impairment may have increased abaloparatide exposure that may increase the risk of adverse reactions; therefore, monitor for adverse reactions. Abaloparatide may exacerbate urolithiasis in patients with active or a history of urolithiasis. If active urolithiasis or preexisting hypercalciuria is suspected, measurement of urinary calcium excretion should be considered.